Antithrombotic Drugs Market Growth Worth $105.33 Billion By 2032 | CAGR: 8.1%

Antithrombotic Drugs Market Size Worth $105.33 Billion By 2032 | CAGR: 8.1%

The antithrombotic drugs market size is predicted to reach USD 105.33 billion by 2032, in accordance with a new study by Polaris Market Research. The report Antithrombotic Drugs Market By Drug Type (Anticoagulant Drug, Antiplatelet Drug, Thrombolytic Drug); By Route of Administration, By Application, By End User, and Geography - Trend, Analysis, and Forecast, 2024-2032” gives a complete foresight into current market dynamics and contribute analysis on future market growth.

Rising cardiovascular disease incidence is anticipated to fuel market expansion over the forecast period. Some of the key factors propelling the growth of the worldwide antiplatelet medicines market are the rising prevalence of cardiovascular illnesses, an aging population, and a sedentary lifestyle. In both developed and developing economies, cardiovascular illnesses constitute the main cause of death.

For instance, according to data from the American Heart Association, at least 3 to 6 million persons in the United States alone had atrial fibrillation in June 2018, and the figure is expected to rise to 6 to 16 million by the year 2050. 3,658 heart transplants were carried out in the United States in 2020. The states of California (496), Texas (302), Florida (288), and New York performed the most heart transplants (250).

The antiplatelet market is influenced by things including the widespread use of antithrombotic/anticoagulant medications, an increase in thrombotic occurrences, an aging population, and recent pharmaceutical advancements.

The market for antithrombotic/anticoagulant medications is anticipated to expand rapidly throughout the forecast period due to factors including the increased availability of these medications and the prevalence of chronic thrombotic diseases that necessitate long-term medication use.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:

The market for antithrombotic medications is expected to be significantly impacted by COVID-19 infection due to the quick pace of research. According to a study published in the American Journal of Cardiovascular Drugs in 2020, there are currently more than ten clinical trials evaluating the efficacy of antithrombotic medications in COVID-19 patients. Additionally, research is being done on parenteral administration techniques for these medications for using critically ill COVID-19 patients.

Antithrombotic Drugs Market Report Highlights

  • Antiplatelet drugs are expected to dominate the market due to increasing use for clotting as arterial clots comprised primarily of platelets, antiplatelet medications are most effective.
  • Activities by key players in the market for the development of antiplatelet drugs are expected to drive the market growth over the forecast period.
  • Anticoagulant, Thrombolytic, and oral drugs is expected to hold the largest market share during the forecast period. Anticoagulants work by interfering with several blood coagulation pathways, making them closely connected to antiplatelet medications and thrombolytic therapies.
  • Some of the key players operating in the market include Daiichi Sankyo Company, Eli Lilly and Company, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Ko. KG and Aspen Bayer AG, Pfizer, AstraZeneca plc, Johnson & Johnson. AstraZeneca, Otsuka Pharmaceutical, Portola Pharmaceutical Inc., Yuyu Pharma Inc., Limited, Glenmark Pharmaceuticals Limited, China National Pharmaceutical Group Corp, Novartis, Acetlion Pharmaceuticals, Generium Holdings among the others.

Polaris Market Research has segmented the Antithrombotic Drugs market report based on drug type, route of administration, application, end-user and region:

Antithrombotic Drugs market, By Drug Type (Revenue - USD Billion, 2019-2032)

  • Antiplatelet Drug
  • Anticoagulant Drug
  • Thrombolytic Drug

Antithrombotic Drugs market, By Route of Administration (Revenue - USD Billion, 2019-2032)

  • Oral
  • Parenteral

Antithrombotic Drugs market, By Application (Revenue - USD Billion, 2019-2032)

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Others

Antithrombotic Drugs market, By End User (Revenue - USD Billion, 2019-2032)

  • Hospitals
  • Ambulatory Surgery Centres
  • Emergency Service Centres
  • Others

Antithrombotic Drugs market, Geography (Revenue - USD Billion, 2019-2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa